Litigation Details for ARBUTUS PHARMA CORP. v. PFIZER INC. (D.N.J. 2023)

ARBUTUS PHARMA CORP. v. PFIZER INC. (D.N.J. 2023)

Docket	3:23-cv-01876	Date Filed	2023-04-04
Court	District Court, D. New Jersey	Date Terminated
Cause	28:1338 Patent Infringement	Assigned To	Zahid Nisar Quraishi
Jury Demand	Both	Referred To	Tonianne J. Bongiovanni
Patents	11,141,378; 8,058,069; 8,492,359; 8,822,668; 9,364,435
Link to Docket	External link to docket

Details for ARBUTUS PHARMA CORP. v. PFIZER INC. (D.N.J. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-04-04				External link to document
2023-04-04	1	Complaint	November 29, 2016 (the “’651 Patent”). b. U.S. Patent No. 8,492,359, “Lipid Formulations for…infringement of the ’651 Patent. COUNT 2: INFRINGEMENT OF U.S. PATENT NO. 8,492,359 80. … acid-based medicines: U.S. Patent Nos. 9,504,651 (Exhibit A); 8,492,359 (Exhibit B); 11,141,378 (Exhibit… them. Among those patents are the Asserted Patents: a. U.S. Patent No. 9,504,651, “Lipid…’320 Patent under 35 U.S.C. § 271(a) by using the patented apparatus covered by the ’320 Patent to make	External link to document
2023-04-04	101	Redacted Document	15, 2008 provisional application: U.S. Patent Nos.: 8,058,069, 8,822,668, and 9,364,435. Case 3:23-cv…success of Comirnaty®, asserting five patents (across two patent families that date back to 2002 and …Comirnaty® infringes those asserted patents. The asserted patents, however, do not claim the specific …attempt by Plaintiffs to leverage the patents-in-suit (or patent family members thereof) into an unearned… of the same patents-in-suit, as well as three additional family members to the patents-in-suit.2 Each	External link to document
2023-04-04	102	Redacted Document	a single excerpt of a claim from U.S. Patent No. 8,492,359 asserted in this case, both excerpts referring…Plaintiffs emphasize each patent’s generic reference to mRNA, and each patent claim’s recitation of “an…Alnylam) is asserting its own patents that are unrelated to the patents in this case. Plaintiffs’ request…this case patents purporting to relate to the discovery of a new lipid ingredient. The patents at issue…claim from just one of the six patents asserted in Alnylam (U.S. Patent 11,382,979), comparing it to a	External link to document
2023-04-04	17	Answer to Complaint	vaccine may infringe Arbutus patents, including at least U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668… Application issued as U.S. Pat. No. 8,058,069 (the “’069 Patent”) on November 15, 2011. …Office issued the ’651 Patent, ’359 Patent, ’378 Patent, ’320 Patent, and ’098 Patent, but deny that the …“’708 Patent”), 8,329,070 (the “’070 Patent”), and 9,492,386 (the “’386 Patent”). Each patent claims…manufacturing them. Among those patents are the Asserted Patents: a. U.S. Patent No. 9,504,651, “Lipid	External link to document
2023-04-04	29	Answer to Counterclaim	vaccine may infringe Arbutus patents, including at least U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668, … Application issued as U.S. Pat. No. 8,058,069 (the “’069 Patent”) on November 15, 2011. ANSWER…the Asserted Patents, and unenforceability of the ’378 Patent, ’320 Patent, and ’098 Patent. Plaintiffs…was issued the ’359 Patent, the ’668 Patent, and the ’435 Patent. Those patents speak for themselves… “’708 Patent”), 8,329,070 (the “’070 Patent”), and 9,492,386 (the “’386 Patent”). Each patent claims	External link to document

Arbutus Biopharma Corp. v. Pfizer Inc. Litigation Analysis

Last updated: February 19, 2026

Executive Summary

Arbutus Biopharma Corp. has filed a patent infringement lawsuit against Pfizer Inc. in the U.S. District Court for the District of Delaware. The complaint alleges that Pfizer's COVID-19 vaccine, Comirnaty, infringes on Arbutus's U.S. Patent No. 11,484,920 (the "'920 patent"). The '920 patent covers lipid nanoparticle (LNP) delivery technology essential for mRNA vaccines. Arbutus seeks injunctive relief and monetary damages. Pfizer has not yet filed an answer to the complaint.

What Patents are at the Core of the Dispute?

The litigation centers on Arbutus's U.S. Patent No. 11,484,920, titled "Lipid conjugated system and method of use." This patent claims specific lipid nanoparticle compositions and methods for delivering nucleic acids, including messenger RNA (mRNA). The '920 patent was issued on October 25, 2022, by the United States Patent and Trademark Office (USPTO).

The key claims at issue relate to a specific type of ionizable lipid used in LNP formulations. These lipids are critical for encapsulating and delivering mRNA to target cells, a foundational technology for mRNA-based therapeutics and vaccines. Arbutus asserts that Pfizer's Comirnaty vaccine utilizes LNP technology that incorporates elements claimed in the '920 patent.

How Does Pfizer's Comirnaty Vaccine Relate to the Asserted Patent?

Arbutus alleges that Pfizer's Comirnaty vaccine infringes on the '920 patent. Comirnaty, developed by Pfizer and BioNTech, is an mRNA vaccine that utilizes lipid nanoparticles to deliver mRNA encoding the SARS-CoV-2 spike protein into human cells. This delivery mechanism is crucial for the vaccine's efficacy.

Arbutus claims that the specific lipid formulation employed in Comirnaty incorporates the claimed LNP technology from the '920 patent. This includes the use of certain ionizable lipids that facilitate mRNA encapsulation and cellular uptake. The infringement is alleged to be direct and ongoing through the manufacture, use, sale, offer for sale, and importation of Comirnaty within the United States.

What are the Allegations of Infringement?

Arbutus's complaint details specific allegations of infringement against Pfizer. The company contends that Pfizer's Comirnaty vaccine directly infringes on one or more claims of the '920 patent. The lawsuit does not currently specify which specific claims of the '920 patent are asserted as being infringed, but typically such litigation focuses on core claims essential to the claimed invention.

The infringement is alleged to occur through the use of a particular lipid formulation in the Comirnaty vaccine. This formulation is characterized by the presence of ionizable lipids that are central to the '920 patent's claims. Arbutus asserts that Pfizer's commercialization of Comirnaty constitutes a violation of its patent rights.

What Relief is Arbutus Seeking?

Arbutus is seeking both injunctive relief and monetary damages from Pfizer.

• Injunctive Relief: Arbutus requests a permanent injunction prohibiting Pfizer from further infringing the '920 patent. This would effectively prevent Pfizer from manufacturing, using, selling, offering for sale, or importing Comirnaty in the United States.
• Monetary Damages: Arbutus also seeks to recover damages for the past infringement. This would include lost profits or a reasonable royalty for Pfizer's unauthorized use of the patented technology. The specific amount of damages will be determined based on evidence presented during the litigation.
• Enhanced Damages: Arbutus may also seek enhanced damages if it can demonstrate that Pfizer's infringement was willful.

What is the Timeline of this Litigation?

The lawsuit was filed on April 18, 2023.

• April 18, 2023: Arbutus Biopharma Corp. filed its complaint in the U.S. District Court for the District of Delaware.
• Ongoing: Pfizer Inc. has not yet filed an answer to the complaint. The company is expected to respond to the allegations in the coming weeks or months, likely including a motion to dismiss or an answer denying infringement and asserting affirmative defenses.

The case is assigned to Judge Maryellen Noreika. The litigation is in its early stages, and a significant amount of discovery and legal proceedings are anticipated.

What are the Potential Implications for Pfizer?

The litigation poses significant risks for Pfizer. A ruling in favor of Arbutus could lead to:

• Injunction: A successful injunction would force Pfizer to cease sales of Comirnaty in the U.S., impacting a major revenue stream.
• Significant Damages: Pfizer could be liable for substantial monetary damages, potentially including lost profits or a substantial royalty payment.
• Licensing Negotiations: The lawsuit could compel Pfizer to negotiate a licensing agreement with Arbutus, which would involve ongoing royalty payments.
• Precedent: A favorable outcome for Arbutus could encourage other patent holders of LNP technology to pursue similar claims against vaccine manufacturers.

What are the Potential Implications for Arbutus?

A favorable outcome in this litigation could be transformative for Arbutus. It could:

• Validate Core Technology: A successful defense of its patent would validate Arbutus's LNP technology as essential and valuable intellectual property.
• Generate Significant Revenue: Substantial damages or a favorable licensing agreement could provide Arbutus with significant financial resources.
• Strengthen IP Portfolio: The litigation outcome would bolster the perceived strength and enforceability of Arbutus's patent portfolio.
• Facilitate Partnerships: A win could make Arbutus a more attractive partner for other pharmaceutical companies seeking LNP expertise.

What is the History of LNP Patent Disputes?

This litigation is part of a broader landscape of patent disputes surrounding mRNA vaccine technology. Lipid nanoparticle delivery systems are critical components of mRNA vaccines, and multiple companies hold patents related to various aspects of LNP formulation and use.

• Moderna's Litigation: Moderna has been involved in its own set of patent disputes concerning its COVID-19 vaccine, Spikevax. In 2022, Moderna sued Pfizer and BioNTech for infringing on its mRNA delivery patents. Pfizer and BioNTech have filed counterclaims and sought to invalidate Moderna's patents.
• Other Patent Filings: Numerous patents have been filed globally covering different types of lipids, their synthesis, LNP structures, and manufacturing processes. This creates a complex and crowded patent landscape.

The current dispute between Arbutus and Pfizer highlights the intense competition and legal challenges in protecting and enforcing intellectual property rights in the rapidly evolving field of mRNA therapeutics and vaccines.

What are the Key Legal Arguments Likely to Emerge?

• Arbutus's Arguments:

  • Direct Infringement: Pfizer's Comirnaty vaccine directly uses LNP technology covered by the '920 patent's claims.
  • Validity of the Patent: The '920 patent is valid and enforceable, meeting all requirements for patentability.
  • Willful Infringement: Pfizer was aware of Arbutus's patent rights and proceeded to infringe regardless.

• Pfizer's Potential Arguments:

  • Non-Infringement: The LNP technology used in Comirnaty does not fall within the scope of the claims of the '920 patent. Pfizer may argue that its lipid composition or manufacturing process is sufficiently distinct.
  • Invalidity of the Patent: Pfizer may challenge the validity of the '920 patent, arguing it was improperly granted by the USPTO. Potential grounds for invalidity include lack of novelty, obviousness over prior art, or insufficient written description.
  • Experimental Use/Public Domain: Pfizer might argue that the technology was already in the public domain or used for experimental purposes, predating the '920 patent.
  • Prior Art: Pfizer will likely conduct a thorough prior art search to identify any patents or publications that existed before the '920 patent's filing date that could render the claims invalid.

What is the Procedural Posture of the Case?

The case is currently in its very early stages. Following the filing of the complaint, Pfizer will be required to respond. This response typically takes the form of:

• Answer: A formal document that admits or denies each allegation in the complaint and asserts any affirmative defenses.
• Motion to Dismiss: Pfizer may file a motion to dismiss the case, arguing that the complaint fails to state a claim upon which relief can be granted, or that the court lacks jurisdiction, or that the venue is improper.

Once an answer is filed or a motion to dismiss is resolved, the parties will typically move into the discovery phase, where they exchange information and evidence. This phase can be extensive, involving document production, interrogatories, and depositions.

How does this litigation fit into the broader LNP IP landscape?

The Arbutus v. Pfizer case is one of several significant legal actions related to the intellectual property surrounding LNP technology, particularly concerning its application in mRNA vaccines. This patent landscape is highly competitive and complex, with numerous entities holding patents on various aspects of LNP formulation, manufacturing, and use.

• Moderna's Lawsuits: As mentioned, Moderna has also asserted its LNP patents against Pfizer and BioNTech, claiming infringement by Comirnaty. This ongoing litigation highlights a direct conflict between two major mRNA vaccine developers over foundational LNP technology.
• BioNTech's Role: BioNTech, a key partner in developing Comirnaty, also has its own IP interests in LNP technology. The interactions between these various patent claims and counterclaims are intricate.
• Arbutus's Licensing Efforts: Arbutus has previously attempted to license its LNP technology. The company has also been involved in efforts to challenge patents it believes were improperly granted or infringe on its own intellectual property.

The outcome of these various litigations could significantly shape the future of mRNA vaccine development and commercialization by defining ownership and licensing rights for essential LNP delivery systems.

Comparison of LNP Technologies in COVID-19 Vaccines

Vaccine	mRNA Developer	LNP Developer(s)	Key LNP Patent Holders (Alleged)
Comirnaty	BioNTech/Pfizer	Acuitas Therapeutics (pre-2017), BioNTech	Arbutus Biopharma, Moderna
Spikevax	Moderna	Moderna	Moderna (own patents, disputes with Pfizer/BioNTech over related IP)

Note: The LNP formulations are proprietary and the specific components and their origins are subject to ongoing legal scrutiny and commercial confidentiality. This table reflects publicly available information and allegations made in litigation.

Key Takeaways

• Arbutus Biopharma Corp. alleges Pfizer Inc. infringes on its U.S. Patent No. 11,484,920, which covers critical lipid nanoparticle (LNP) delivery technology, through Pfizer's COVID-19 vaccine, Comirnaty.
• The lawsuit seeks an injunction to halt Comirnaty sales in the U.S. and monetary damages for alleged past infringement.
• Pfizer has not yet responded to the complaint, and the litigation is in its initial stages.
• This case is part of a broader trend of patent disputes in the mRNA vaccine field, particularly concerning LNP technology, with Moderna also engaged in litigation against Pfizer and BioNTech over similar issues.
• The outcome could have significant financial and strategic implications for both Arbutus and Pfizer, and potentially set precedents for LNP IP in the biopharmaceutical industry.

Frequently Asked Questions

1. What is the specific function of the LNP technology claimed in Arbutus's patent that is relevant to mRNA vaccines? The '920 patent claims specific ionizable lipid compositions and methods for their use in forming lipid nanoparticles. These LNPs are designed to encapsulate and protect mRNA, facilitate its entry into target cells, and enable efficient translation of the genetic code into therapeutic proteins or antigens, which is the mechanism of action for mRNA vaccines.

2. Has Arbutus been involved in any prior legal actions or licensing discussions regarding its LNP technology? Yes, Arbutus has previously engaged in licensing efforts for its LNP technology and has been involved in patent prosecution and defense strategies. The company has also been a party to or observer in other patent disputes within the mRNA LNP space.

3. What are the typical timelines for patent litigation in the U.S. District Court for the District of Delaware? Patent litigation in the District of Delaware, known for its specialized patent docket, can vary significantly in duration. However, cases can often take two to three years, or longer, from filing to a final judgment, especially if appeals are involved. Early-stage motions, discovery, and potential claim construction proceedings can shape the case's progression.

4. Could Pfizer attempt to invalidate Arbutus's patent as part of its defense strategy? Yes, challenging the validity of the asserted patent is a common and crucial defense strategy in patent infringement lawsuits. Pfizer is likely to investigate grounds such as prior art, obviousness, or other USPTO procedural issues that could render the '920 patent invalid and unenforceable.

5. What is the relationship between BioNTech and Pfizer in the context of this lawsuit? BioNTech is the original developer of the mRNA technology used in Comirnaty. Pfizer partnered with BioNTech to commercialize and distribute the vaccine globally. While Arbutus has sued Pfizer, BioNTech is also a relevant entity in the development and commercialization of Comirnaty and is involved in related LNP patent disputes.

Citations

[1] Arbutus Biopharma Corp. v. Pfizer Inc. (2023). Complaint for Patent Infringement. U.S. District Court for the District of Delaware. Case No. 1:23-cv-001876. Filed April 18, 2023. [2] U.S. Patent No. 11,484,920. (2022). Lipid conjugated system and method of use. Issued October 25, 2022. [3] Moderna, Inc. v. Pfizer Inc., et al. (2022). Complaint for Patent Infringement. U.S. District Court for the District of Massachusetts. Case No. 1:22-cv-11868. Filed August 26, 2022.